Other Events ·
Jasper Therapeutics, Inc. received a written notice from Nasdaq indicating that its voting common stock has failed to…
JSPRJasper Therapeutics, Inc.
Jasper Therapeutics, Inc. received a written notice from Nasdaq indicating that its voting common stock has failed to meet the minimum $1.00 per share bid price requirement for continued listing on the Nasdaq Capital Market. The company has been granted an initial 180-day period, ending November 30, 2026, to regain compliance, with the possibility of an additional 180-day period if other requirements are met. Jasper Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions.